Clinical Trial: NCT03462719
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Janssen Research & Development, LLC |
| Information Provided By: | Janssen Research & Development, LLC |
| Last Update Posted: | 2026-11-03 |
Study Overview
Brief Summary
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).
Official Title
A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Intervention / Treatment
- Drug: Ibrutinib
- Drug: Venetoclax
- Drug: Chlorambucil
- Drug: Obinutuzumab
- Drug: Ibrutinib (as Subsequent Therapy)
Other Study ID Numbers
- CR108428
- 2017-004699-77
- 54179060CLL3011
- 2017
Start Date (Actual)
2018-04-17
Primary Completion Date (Actual)
2021-02-26
Study Completion Date (Estimated)
2029-04-05
Enrollment (Actual)
211
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Janssen Research & Development, LLC |
| Information Provided By: | Janssen Research & Development, LLC |
| Last Update Posted: | 2026-11-03 |
Study Overview
Brief Summary
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).
Official Title
A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Intervention / Treatment
- Drug: Ibrutinib
- Drug: Venetoclax
- Drug: Chlorambucil
- Drug: Obinutuzumab
- Drug: Ibrutinib (as Subsequent Therapy)
Other Study ID Numbers
- CR108428
- 2017-004699-77
- 54179060CLL3011
- 2017
Start Date (Actual)
2018-04-17
Primary Completion Date (Actual)
2021-02-26
Study Completion Date (Estimated)
2029-04-05
Enrollment (Actual)
211
Study Type
Interventional
Phase
Phase 3